To be realistic I'm not expecting NPAT 15% for the next 1-2 years, as the ship is just turning.
Sustainable Revenue growth is the most significant sign of positive, outlook suggest FY25 will way overpass the $400-450m revenue mark, as revenue increase the Direct Opex will be substantially lower and the margin will rise further.
Also the 2nd half net loss includes the $33m settlement payout and the Earn-out payment, so the real loss is much lower.
When approach NPAT break-even the ratio of less than 1 ( revenum $400-450m vs MC $370)will be screamingly cheap.
- Forums
- ASX - By Stock
- MYX
- What MYX chart shouts
MYX
mayne pharma group limited
Add to My Watchlist
1.15%
!
$5.28

What MYX chart shouts, page-261
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$5.28 |
Change
0.060(1.15%) |
Mkt cap ! $426.5M |
Open | High | Low | Value | Volume |
$5.29 | $5.29 | $5.15 | $45.47K | 8.702K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 491 | $5.26 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$5.28 | 183 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 491 | 5.260 |
4 | 138 | 5.250 |
3 | 508 | 5.240 |
2 | 901 | 5.230 |
2 | 542 | 5.220 |
Price($) | Vol. | No. |
---|---|---|
5.280 | 183 | 4 |
5.290 | 890 | 4 |
5.300 | 1805 | 3 |
5.310 | 400 | 2 |
5.320 | 73 | 2 |
Last trade - 11.57am 18/06/2025 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online